Hypothesis

Combining nicotinamide riboside (NR) supplementation with intermittent fasting (IF) will increase SIRT1 activity specifically in human skeletal muscle, leading to enhanced mitochondrial function and improved aerobic capacity, whereas NR alone will not produce these changes.

Background

Oral NR (500–1200 mg/day) reliably doubles blood NAD+ within 1–2 weeks【1】【2】, yet no human trial has directly measured SIRT1 activation【3】. Tissue NAD+ pools, especially in muscle, may not rise proportionally to circulating levels, and fasting‑induced elevations in the NAD+/NADH ratio via NAMPT upregulation have only been shown in mice【4】【5】. The synergistic potential of IF and NR remains untested in humans.

Mechanistic rationale

1. NR supplies NAD+ precursors that can be converted to NAD+ via the Nrk pathway, increasing the substrate pool for sirtuins.
2. IF raises intracellular NAD+ by stimulating NAMPT expression and shifting the NAD+/NADH ratio toward oxidation, a condition that favors SIRT1 deacetylase activity.
3. SIRT1 activation requires both NAD+ and a permissive cellular context; fasting‑activated AMPK can phosphorylate and potentiate SIRT1, while NR ensures substrate availability.
4. In skeletal muscle, SIRT1 deacetylates PGC‑1α and FOXO1, driving mitochondrial biogenesis and oxidative fiber remodeling. Thus, the combined stimulus should produce a measurable increase in SIRT1‑dependent deacetylation events and downstream mitochondrial adaptations.

Testable predictions

• Prediction 1: Muscle NAD+ concentration (measured by biopsy‑based LC‑MS) will be significantly higher after 4 weeks of NR + IF compared with NR alone or IF alone.
• Prediction 2: SIRT1 activity, assessed by the deacetylation status of PGC‑1α (acetyl‑lysine immunoprecipitation followed by western blot), will rise only in the NR + IF group.
• Prediction 3: Mitochondrial respiratory capacity (high‑resolution respirometry of permeabilized fibers) and VO₂max will improve significantly in the NR + IF arm, with no change in the NR‑only arm.
• Prediction 4: If SIRT1 activation is blocked (e.g., with the selective inhibitor EX‑527 administered locally via intramuscular injection), the NR + IF‑induced improvements in mitochondrial function will be abolished.

Experimental design

A randomized, crossover trial in 30 healthy, sedentary adults (age 20–40). Each participant completes three 4‑week interventions separated by 4‑week washouts: (a) NR 500 mg daily, (b) IF (16:8 time‑restricted eating, 5 days/week), (c) NR + IF. Primary outcomes: muscle NAD+ (biopsy), SIRT1‑target deacetylation (PGC‑1α, FOXO1), mitochondrial respiration (OXPHOS capacity), and VO₂max. Secondary outcomes: circulating NAD+, NAD+/NADH ratio, insulin sensitivity, and self‑reported fatigue.

Potential outcomes and falsifiability

• Support: NR + IF yields a ≥30 % increase in muscle NAD+, a ≥20 % rise in SIRT1‑mediated deacetylation, and a ≥5 % improvement in VO₂max relative to NR alone; these changes are prevented by EX‑527.
• Refutation: No significant differences in muscle NAD+, SIRT1 activity, or functional endpoints between NR + IF and NR alone, or the effects are not attenuated by SIRT1 inhibition. This would falsify the hypothesis that IF augments NR‑driven SIRT1 activation in human muscle.

By directly linking precursor supply, fasting‑induced redox shifts, and enzyme‑specific activity, this hypothesis moves beyond correlative NAD+ measurements to a mechanistic, falsifiable claim about sirtuin signaling in humans.